Bolt Biotherapeutics (BOLT) announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a Boltbody ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and the company is in the process of modifying the clinical trial protocol to allow for step-up dosing, which has been successfully used commercially for T-cell engagers. BDC-4182 preclinical data supports this approach. As a result of the update to the clinical trial protocol for BDC-4182, Bolt now expects to report initial clinical data in the third quarter of 2026. To conserve capital and maintain long-term shareholder value, the company is implementing a workforce reduction of approximately 50%, extending its cash runway into 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT:
- Bolt Biotherapeutics Reports Reduced Losses and Revenue Growth
- Cautious Hold Rating on Bolt Biotherapeutics Amid Uncertain Trial Outcomes and Financial Sustainability
- Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split
- Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)